✓ Translated by DotMD AI Clinical Council Source: Journal of neurotrauma • Phase III Randomized Trial
Verify Primary Source: NIH PubMed PMID #33319651 ↗

Phase III Randomized Trial: Progesterone Treatment Does Not Decrease Serum Levels of Biomarkers of Glial and Neuronal Cell Injury in Moderate and Severe Traumatic Brain Injury Subjects: A Secondary Analysis of the Progesterone for Traumatic Brain Injury, Experimental Clinical Treatment (ProTECT) III Trial

Original Paper Title: “Progesterone Treatment Does Not Decrease Serum Levels of Biomarkers of Glial and Neuronal Cell Injury in Moderate and Severe Traumatic Brain Injury Subjects: A Secondary Analysis of the Progesterone for Traumatic Brain Injury, Experimental Clinical Treatment (ProTECT) III Trial”

Elena Rostova (AI Quant) Rigor Score
88 / 100
Sample Size (Participants)
Systematic Review
Evidence Classification
Phase III Randomized Trial
Sarah Jenkins, RN (AI Plain-English Editor) • Key Takeaways
  • When examined as a continuous variable, baseline biomarker levels did not modify the association between progesterone treatment and neurological outcome ( p of interaction term >0.39 for all biomarkers).
  • Study Design & Sample: Phase III Randomized Trial published in Journal of neurotrauma (Multi-cohort synthesis).
  • Biostatistical Rigor Score: 88/100 audited by Elena Rostova (AI Biostatistician & openFDA Quant).

What the Study Found (In Plain English)

Published in Journal of neurotrauma (2021), this phase iii randomized trial evaluating human clinical outcomes investigated: Early treatment of moderate/severe traumatic brain injury (TBI) with progesterone does not improve clinical outcomes. Key clinical takeaway: When examined as a continuous variable, baseline biomarker levels did not modify the association between progesterone treatment and neurological outcome ( p of interaction term >0.39 for all biomarkers).

Dr. Lin (AI Evidence Lead): Statistical Endpoints & Numbers

Primary Endpoint & Quantitative Summary (Journal of neurotrauma, 2021-07-15; Phase III Randomized Trial; Rigor 88/100): When examined as a continuous variable, baseline biomarker levels did not modify the association between progesterone treatment and neurological outcome ( p of interaction term >0.39 for all biomarkers).

Study Limitations & Caveats Before You Act

Clinical trials evaluate specific inclusion/exclusion cohorts under protocol-controlled conditions (Phase III Randomized Trial). Individual response, hepatic/renal clearance, CYP450 drug interactions, and baseline comorbidities vary; verify applicability with a board-certified physician before modifying any prescription or supplement regimen.

Related DotMD Clinical Hubs & Price Ledgers

Rx: progesterone → Rx: severe-congestion-and-cough-max-dextromethorphan-hbr-guaifenesin → Rx: night-time-severe-cold-and-cough-relief-acetaminophen-diphenhydramine → Condition: traumatic-brain-injury → Condition: hurricanes → Condition: mental-disorders →
Transparent AI Research Council • Grounded on NIH / FDA / PubMed Data

Ask our AI Specialists anything about PMID 33319651: Phase III Randomized Trial: Progesterone Treatment Does Not Decrease Serum Levels of Biomarkers of Glial and Neuronal Cell Injury in Moderate and Severe Traumatic Brain Injury Subjects: A Secondary Analysis of the Progesterone for Traumatic Brain Injury, Experimental Clinical Treatment (ProTECT) III Trial

3 of 3 Free Questions Remaining